by Michael Lachman
Four years following Food & Drug Administration (FDA) approval of the anti-VEGF (vascular endothelial growth factor) drug ranibizumab ( Lucentis) from Genentech Inc./Roche, this new drug class remains the standard of care for the treatment of neovascular (wet) age-related macular degeneration (AMD) and has been widely adopted for off-label treatment of other retinal diseases
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?